AYTU BIOPHARMA, INC Inventory, Finished Goods, Net of Reserves
AYTU BIOPHARMA, INC (AYTU) had Inventory, Finished Goods, Net of Reserves of $3.40 million as of 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-09-22
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $3.40M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $4.04M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $5.63M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $7.87M.
| Period end | Inventory, Finished Goods, Net of Reserves | Inventory, Finished Goods, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $3.40M 10-K · filed 2026-09-22 | |
| 2026-03-31 | $4.04M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $5.63M 10-Q · filed 2026-02-03 | |
| 2025-09-30 | $7.87M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $8.94M 10-K · filed 2026-09-22 | |
| 2025-03-31 | $8.46M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $7.49M 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $7.66M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $6.15M 10-K · filed 2025-09-23 | $6.64M 10-K · filed 2024-09-26 |
| 2024-03-31 | $6.32M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $8.67M 10-Q · filed 2024-02-14 | |
| 2023-09-30 | $7.71M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $7.74M 10-K · filed 2024-09-26 | |
| 2023-03-31 | $8.60M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $8.36M 10-Q · filed 2023-02-21 | |
| 2022-09-30 | $8.38M 10-Q/A · filed 2023-02-21 | |
| 2022-06-30 | $7.20M 10-K · filed 2023-10-12 | |
| 2022-03-31 | $9.87M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $11.96M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $10.67M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $10.72M 10-K · filed 2022-09-27 | |
| 2021-03-31 | $10.81M 10-Q · filed 2021-05-17 | |
| 2020-06-30 | $9.60M 10-K · filed 2021-09-28 | $9.60M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |